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The bacterial cell wall muramyl dipeptides MDP and glucosaminyl-MDP (GMDP) are powerful
immunostimulators but their binding target remains controversial. We previously reported expres-
sion cloning of GMDP-binding polypeptides and identiﬁcation of Y-box protein 1 (YB-1) as their sole
target. Here we show speciﬁc binding of GMDP to recombinant YB-1 protein and subcellular colocal-
ization of YB-1 and GMDP. GMDP binding to YB-1 upregulated gene expression levels of NF-jB2, a
mediator of innate immunity. Furthermore, YB-1 knockdown abolished GMDP-induced Nfkb2
expression. GMDP/YB-1 stimulation led to NF-jB2 cleavage, transport of activated NF-jB2 p52 to
the nucleus, and upregulation of NF-jB2-dependent chemokine Cxcr4 gene expression. Therefore,
our ﬁndings identify YB-1 as new target for muramyl peptide signaling.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Muramyl dipeptides MDP and GMDP are potent adjuvants and
immunostimulators released from the cell wall of invading bacte-
ria by the action of lysozyme and amidases, and synergize with
lipopolysaccharide (LPS) in the induction of the innate
immune response [1–3]. MDP is composed of N-acetylmuramic
acid linked to the N-terminus of an L-alanine D-isoglutamine
dipeptide, whereas GMDP bears an additional N-terminalacetyl-glucosamine moiety. The two molecules have similar bioac-
tivity and are thought to target the same binding sites and signal-
ing pathways. Understanding the precise mechanisms underlying
MDP/GMDP immunostimulatory effects is important for the man-
agement of immune and inﬂammatory disorders associated with
dysregulation of innate immunity, including Crohn’s and inﬂam-
matory bowel diseases, atherosclerosis, arthritis, systemic lupus,
and type I diabetes.
The precise molecular target(s) for peptidoglycan-derivedmole-
cules remain controversial. Most attention has focused on NOD
(nucleotide oligomerization domain)-type pattern-recognition
receptors (PRRs). NOD2, encoded by the CARD15 gene in human,
has been proposed as a sensor for cell-wall peptidoglycans [4–6].
NOD2 protein is expressed in cells of the innate immune system
including macrophages, polymorphonuclear neutrophils, and den-
dritic cells. These respond to NOD2 stimulation by the induction
of nuclear factor (NF)-jB and cytokine secretion [3,7–9], although
some aspects of NOD signaling are thought to take place indepen-
dently of NF-jB activation [10]. Notably, Nod2 knockout in mice
impaired responses to MDP [11–13] and, conversely, expression
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forms of human NOD2 are associated with human inﬂammatory
disorders [15–17].
Although MDP appears to require NOD2 for full activity, there is
controversy concerning the primary receptor for MDP binding. It
was ﬁrst reported that NOD2 lacks any detectable afﬁnity for
immobilized MDP [18], and calretinin was suggested as a receptor
target. A subsequent report described binding of puriﬁed NOD2
protein to biotinylated MDP, but excess biotinylated MDP retained
only 3% of NOD2 protein [19]. More recently direct binding of
MDP to partially puriﬁed recombinant NOD2 protein produced in
insect cells was described [20]. It remains an open question
whether muramyl peptides bind exclusively to NOD2 or if other
targets including calretinin contribute to the immunomodulatory
activity of MDP. We therefore addressed the possibility that mura-
myl peptides might target an alternative receptor.
In earlier work we used monoclonal antibody against GMDP to
probe a phage display library; this detected a GMDP mimetic pep-
tide denoted ‘RN-15’ (RVPPRYHAKISPMVN) that, similarly to
GMDP/MDP, augments antibody and cytokine responses in vivo
following immunization, although it differs from GMDP in that it
lacks pyrogenic activity [21]. More recently we reported expres-
sion cloning of GMDP-binding polypeptides from mouse spleno-
cytes: all clones identiﬁed multifunctional factor YB-1 as a
speciﬁc target for GMDP [22].
In the present report we extend these preliminary ﬁndings. We
now address speciﬁc GMDP binding to YB-1 and demonstrate that
such binding leads to functional activation and induction of che-
mokine gene expression.
2. Methods
Regents used in this work including mouse monoclonal anti-
body to YB-1 were described previously [22]; further experimental
details can be found in the Supplementary Methods online.
Recombinant YB-1 was expressed in Escherichia coli, and puriﬁed
as described previously [22,43,44].
Experiments use both WEHI-3 and bone marrow-derived den-
dritic cells. WEHI cells were grown as described (Supplementary
Methods). Bone-marrow cells were prepared and subjected to den-
dritic maturation using recombinant GM-CSF. For knockdown of
YB1 the antisense oligonucleotide was 50-GGG TCC TCC ACG CAA
TTA C-30; the control oligonucleotide of the same G+C content was
50-TTG ATC TCG CTG CGG TGA A-30; these were stably expressed
under a PolIII promoter following transfection and drug selection.
Nfkb2 transcript levels were measured by qPCR using primers
50-ATG CCT GAT TTT GAG GGA CTA TAC CCT GTA-30 and 50-GAC
TTGGTGGGTCTA TTGGAGGCCTTGTC-30 locatedwithin the down-
stream coding region of Nfkb2, and which identiﬁes all major splice
variants. Gapdh internal control primers were 50-GAC CAC AGT CCA
TGC CAT CA-30 and 50-TGA AGT CGC AGG AGA CAA CC-30 and Cxcr4
primers were 50-ATG GAA CCG ATC AGT GTG AGT ATA TAC AC-30
and 50-CAA AAA TTT CCC AAA GTA CCA GTC AGC C-30.
For GMDP binding, primary mouse splenocytes were incubated
with FITC-GMDP in the presence or absence of unlabeled GMDP
(concentrations as speciﬁed in ﬁgure legends). After 2 h at 37 C
and washing cell lysates were prepared as before. Lysates were
incubated with equal concentrations (as given previously) of
biotinylated antibodies against YB-1 (puriﬁed mouse monoclonal,
IgG) or with a control nonspeciﬁc antibody (puriﬁed total Ig from
unimmunized mice, predominantly IgG). Antibody complexes
were collected by binding to streptavidin–magnetic beads as
before. FITC ﬂuorescence was measured spectroﬂuorimetrically
(excitation, 494 nm; emission 520 nm) on a Lumina ﬂuorescence
spectrometer.For confocal microscopy, cells were activated with GMDP or
FITC-GMDP for 4 h; nuclear stain Hoechst 33342 was added for
the last hour of incubation. Cells were ﬁxed/permeabilized (2%
paraformaldehyde, 0.1% Triton X-100), washed, and stained with
mouse antibody to YB-1 and developed with secondary
anti-mouse IgG-AlexaFluor 555. Images were collected using an
Eclipse E2000 confocal microscope (Nikon, Japan) equipped with
405, 488, and 514 nm lasers.
To analyze activation of NF-jB2 cleavage and nuclear transloca-
tion, primary mouse splenocytes were incubated with different
combinations of GMDP and YB-1 for 4 h. Cells were lyzed, sepa-
rated into nuclear and cytoplasmic fractions by centrifugation
(10 min, 3000g, 4 C), and fractions analyzed by western blotting
using a speciﬁc mouse antibody to NF-jB2 (Sc-298, Santa Cruz
Biotechnology) that reacts with both the p100 precursor and the
p52 activated cleavage product. After washing, the blot was devel-
oped using conjugated rabbit anti-mouse antibody as before and
chemiluminescent substrate (Pierce ECL western blotting substrate
32106).
3. Results and discussion
We addressed direct binding of GMDP to YB-1 using ﬂuorescent
(FITC, ﬂuorescein isothiocyanate)-labeled GMDP. Following incu-
bation of primary mouse splenocytes with FITC-GMDP, extracts
were immunoprecipitated with monoclonal antibody against
YB-1; the complexes were disrupted and supernatants were exam-
ined for released FITC ﬂuorescence. As shown in Fig. 1A, primary
antibody against YB-1 retained FITC ﬂuorescence (520 nm),
whereas control antibody did not, demonstrating that YB-1 is pre-
sent in a complex with FITC-GMDP. The ﬂuorescence signal was
abolished by excess unlabeled GMDP, demonstrating the speci-
ﬁcity of the interaction.
We previously reported, using recombinant YB-1, that GMDP
competes with FITC-GMDP for binding to YB-1 [22]. To estimate
the extent of the association, we incubated a ﬁxed concentration
of FITC-GMDP with increasing amounts of YB-1 and examined
retention of ﬂuorescence by anti-YB-1 antibody. As shown in
Fig. 1B, ﬂuorescence retention was proportional to input YB-1, with
saturation at approximately isomolar concentrations of YB-1 and
FITC-GMDP, indicative of a 1:1 complex between the two
molecules.
To provide further evidence for GMDP binding to YB-1 we
examined their subcellular distributions in cells treated with
labeled GMDP. Confocal ﬂuorescence microscopy was performed
on mouse bone marrow-derived dendritic cells using FITC-GMDP
(yellow-green) in conjunction with ﬂuorescent antibody (red)
against YB-1. As shown in Fig. 2, GMDP colocalizes with YB-1
within predominantly cytoplasmic complexes. These observations
are consistent with GMDP/YB-1 complex formation.
To address whether GMDP binding to YB-1 is functionally
active, we examined the expression of nuclear factor jB2
(NF-jB2), a key mediator of the induction of innate immunity, in
response to GMDP and YB-1. In a ﬁrst experiment, the mouse
monocyte WEHI-3 cell line was incubated with GMDP and/or
recombinant YB-1. As shown in Fig. 3A, control cells showed
marked upregulation by both GMDP and YB-1, with maximal
upregulation in the presence of both added factors.
Because these cells endogenously express YB-1, and GMDP
alone brought signiﬁcant upregulation of Nfkb2 gene expression
(Fig. 3A, left), we performed YB-1 knockdown of YB-1. Stable trans-
formants of mouse monocyte cell line WEHI-3 expressing YB-1 or
control antisense siRNA of the same G+C content were analyzed for
Nfkb2 expression in response to GMDP. Knockdown robustly
reduced both YB-1 protein and mRNA levels (Supplementary
Fig. 1. GMDP binds to YB-1. (A) FITC-GMDP is present in YB-1 complexes and is competed by GMDP. Emission intensities of anti-YB-1 immune complexes from mouse
primary splenocytes treated with FITC-GMDP (10 lg/ml) were normalized to the mean signal (520 nm) retained by anti-YB-1 antibody (100%). Lane 1, ﬂuorescence retention
by nonspeciﬁc antibody (Ab) in splenocytes treated with FITC-GMDP. Lane 2, ﬂuorescence of FITC-GMDP (10 lg/ml)-treated splenocytes retained by anti-YB-1 Ab. Lane 3, as
in lane 2 but where cells were incubated with excess unlabeled GMDP (10 lg/ml FITC-GMDP + 100 lg/ml GMDP). Values are means +/ S.D. of triplicate replicates. (B)
Titration of FITC-GMDP retention using a ﬁxed concentration of FITC-GMDP (100 nM) and escalating concentrations of YB-1 (0–120 nM); the plot shows ﬂuorescence retained
by anti-YB-1 Ab. Values are means of two independent replicates. Controls: s, polyclonal mouse IgG replaced anti-YB-1; , ovalbumin (120 nM) replaced YB-1.
Fig. 2. Subcellular colocalization of GMDP with YB-1. Mouse primary dendritic cells were incubated with ﬂuorescent-labeled GMP and/or antibody against YB-1. (A) Hoechst
33342 counterstain (blue). (B) FITC-GMDP (yellow-green). (C) AlexaFluor 555-anti-YB1 (red). (D) Superimposition of (A–C); enlarged.
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by GMDP was largely abolished (Fig. 3A, right) whereas the control
antisense had no effect (Supplementary Fig. S2). Importantly,
GMDP-induced upregulation of Nfkb2 was restored in YB-1 knock-
down cells by exogenous recombinant YB-1 protein (1 lg/ml)
(Fig. 3A, right). These results demonstrate that YB-1 is essential
for induction of Nfkb2 expression by GMDP.
MDP and GMDP contain a key L-Ala D-isoGln dipeptide that is
required for biological activity. To conﬁrm the speciﬁcity of the
YB-1/GMDP interaction we used biologically inert LL-GMDP in
which the L-Ala-D-isoGln grouping is replaced by inactive
L-Ala-L-isoGln [6]. This was tested for induction of Nfkb2 expression
in a standard assay as before. As shown in Fig. 3B, LL-GMDP was
inactive in stimulating Nfkb2 induction. To exclude the possibilitythat contaminating bacterial LPS might contribute to the activity
of recombinant YB-1 protein, the protein was pre-treated with
trypsin; this abolished Nfkb2 induction (Supplementary Fig. S3).
A key issue raised by this work was whether the expression of
NF-jB2 induced by GMDP and YB-1 is functional. To address this,
we ﬁrst examined whether NF-jB2 protein is activated by
GMDP/YB-1 stimulation. Following cell activation the NF-jB2
p100 precursor protein is cleaved to generate the active p52 frag-
ment that is then translocated into the nucleus where it activates
transcription of target genes [23]. We therefore examined
NF-jB2 cleavage and subcellular distribution following treatment
with GMDP and/or YB-1. Accurate separation of nuclear and cyto-
plasmic was conﬁrmed by western blotting for nuclear (CREB) and
cytoplasmic (GAPDH) markers (Fig. S4).
Fig. 3. Absence of NfkB2 induction in YB-1 knockdown cells or with the inert isomer LL-GMDP. (A) Monocyte cells (WEHI-3) stably expressing siRNA to YB-1 or a control
siRNA were incubated for 2 h at 37 C in the presence or absence of GMDP (10 lg/ml) and/or recombinant YB-1 protein (1 lg/ml), and levels of Nfkb2 mRNA determined by
qPCR. Upper panel, representative Nfkb2 transcript levels from qPCR; Gapdh, internal control. Lower panel, Nfkb2 expression levels (normalized to internal control; arbitrary
units) are representative of three independent replicates under slightly different conditions. (B) Above: representative Nfkb2 transcript levels from quantitative PCR of
stimulated mouse WEHI-3 cells; below, band intensities; values are relative to coampliﬁed Gapdh transcript levels and were normalized to maximal stimulation (third lane,
100%). Values are means +/ S.D. from three independent replicates. In the fourth lane LL-GMDP (10 lg/ml) replaced GMDP.
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or its cleavage product p52. Treatment with either GMDP or YB-1
led to a small increase in cytoplasmic p52 levels; however, the
combination of both GMDP and YB-1 led to a signiﬁcant increase
in levels of both p100 and p52. The combination also promoted
nuclear translocation of p52 (Fig. 4). Although some nuclear p52
was present in the absence of exogenous YB-1, which we ascribe
to endogenous YB-1, again the combination of YB-1 and GMDP
led to the greatest increase in nuclear levels of p52 (Fig. 4). We con-
clude that GMDP, with YB1, leads to activation and nuclear trans-
port of NF-jB2.
To conﬁrm that NF-jB2 activation and nuclear transport are
functional in transcriptional activation, we next examined the
levels of mRNA for a known NF-jB2-activated gene, Cxcr4, that
encodes the chemokine (C-X-C motif) receptor 4, also known as
fusin or LESTR. CXCR4 is widely expressed in hematopoietic cells
including lymphocytes, monocytes, macrophages, neutrophils,
and eosinophils, and plays a key role in virus infection, innate
immunity, and cancer [24,25]. Speciﬁcally, Cxcr4 transcription is
known to be induced via NF-jB2-dependent pathways [26–28].
As shown in Fig. 4, expression of Cxcr4 was prominently upreg-
ulated by GMDP and YB-1. Although some induction was obtained
with GMDP alone, which we ascribe to endogenous YB-1 expres-
sion (see Fig. 3A), maximal induction of Cxcr4 was with the combi-
nation of GMDP plus YB-1, conﬁrming functional activation of
NF-jB2-dependent transcription.
In summary, we suggested previously that GMDP may bind to
multifunctional factor YB-1 [22], this is conﬁrmed by direct bind-
ing assays in the present work. Because we have shown that
GMDP/YB-1 induces Nfkb2 gene expression, followed by cleavage
and nuclear translocation of NF-kB2 protein, accompanied by
upregulation the expression of a known NF-jB2-dependent gene,
Cxcr4, we conclude that NF-jB2 induced by GMDP/YB-1 is func-
tionally active. These ﬁndings demonstrate that cell stimulation
with GMDP/YB-1 leads to cellular reprogramming and upregula-
tion of innate immune pathway signaling. We conclude that bind-
ing to YB-1 contributes to the adjuvant and immunostimulatory
activity of bacterial muramyl peptides.YB-1 is a multifunctional transcription factor implicated in
innate immunity by modulating the expression of multiple cytoki-
nes, chemokines, and their receptors, and also binds to RNA where
it regulates mRNA stability and translation [29,30]. The importance
of YB-1 is underlined by the ﬁnding that mice genetically deﬁcient
for YB-1 die in utero [31]. YB-1 is also secreted from the cell where
it binds to cell surface Notch3 receptors [32], and there is evidence
that YB-1 expression is induced in response to bacterial infection:
for example, extracellular YB-1 is found in the serum of sepsis
patients but not in healthy controls [33].
The ﬁnding that GMDP targets YB-1 adds a further dimension to
the biological activity of GMDP because NOD2 has been regarded
as a primary binding target for muramyl peptides. However, the
evidence is not entirely consistent [18–20]. Furthermore, in macro-
phages, MDP can induce caspase-1 activation and IL-1 induction by
a pathway independent of NOD2 [34], and the mitogenic and adju-
vant activities of MDP can be separated [35]; these ﬁndings indi-
cate that muramyl peptides have more than one target.
Overall, the evidence presented here argues that multifunctional
factor YB-1 provides a binding target for the biological action of
the muramyl peptide GMDP. Further experiments will be neces-
sary to address potential interactions between NOD2 and YB-1
signaling.
An important issue concerns the domain of interaction between
YB-1 and GMDP. YB-1 is a highly conserved nucleic acid-binding
protein with multiple biological functions in transcription and
translation [29,36,37]. Although generally thought of as a cytosolic
protein, YB-1 applied extracellularly is taken up into the cell
(Fig. S5) and retains biological activity [32,38], as conﬁrmed in
the present report. Conversely, approximately 25% of YB-1 is
secreted into the medium following LPS stimulation of monocytes
[38]. It has been argued that YB-1 export follows a non-canonical
pathway shared by IL-1b, macrophage inhibitory factor (MIF),
and transcription factor HMGB1 [32,38]. YB-1 thus appears to be
a member of a specialized class of proteins that can cycle between
the nucleus, cytosol, membrane, and the extracellular milieu, and
as such are candidates for involvement in aspects of cell–cell para-
crine signaling.
Fig. 4. Nuclear translocation of NF-jB2 protein by GMDP/YB-1 and induction of
Cxcr4 expression. (A) Western blotting of cytoplasmic and nuclear fractions of NF-
jB2 proteins p100 and activated p52 in primary mouse splenocytes treated with
GMDP and/or YB-1 as indicated; NF-jB2 proteins were detected using speciﬁc anti-
NF-jB2 antibody; M, molecular weight markers (kDa). Results are representative of
two independent replicates. Accurate separation of cytoplasmic and nuclear
fractions was conﬁrmed by western blotting (Supplementary Fig. S4). (B)
Induction of Cxcr4 mRNA following treatment of primary splenocytes with GMDP
and/or YB-1. Gapdh provided the loading control. Results are means and SDs of
three independent replicates; the upper panel shows representative qPCRs for Cxcr4
and Gapdh (single qPCR results); statistical analysis (Student t test) conﬁrms the
signiﬁcance of inter-lane differences: *, P = <0.05; ⁄⁄, P = < 0.01; ns, not signiﬁcant.
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to YB-1/GMDP complexes. YB-1 can act as a binding partner for
Notch3 and promote the activation of Notch3 target genes [32].
Interestingly, NOD2 has been implicated in activation of another
Notch family protein, Notch1, in macrophages [39]. We do not
exclude the possibility that, in intact cells, YB-1 and GMDP are part
of a larger complex that might include NOD and Notch proteins,
but this remains to be addressed.
Finally, the YB-1 system could also contribute to the induction
of innate immunity by viral ssRNA because YB-1 has both DNA-
and RNA-binding activity [40–42]; further experiments will be
necessary to investigate this possibility.
In conclusion, the identiﬁcation of YB-1 as a component of the
innate immunity signaling system induced by bacterial muramyl
dipeptides will assist efforts to develop small-molecule therapeu-
tics that can modulate inappropriate or insufﬁcient immunological
responses, and which would therefore have potential wide applica-
tion in the treatment of human disease.Conﬂict of interest
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